Clear Cell Renal Cell Carcinoma

Publication Date: October 9, 2023

Key Points

Key Points

  • Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
  • Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
  • This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).

Diagnosis

...agnosis

Recommendation 1.1The diagnosis of metastatic...


...1.2Radiographic diagnosis of metastatic cle...


Treatment

...reatment

...2.1Select patients (see Practical Information) wit...


...ndation 3.1Select patients with metastati...


...1. First-Line Treatmenta Select ca...


...endation 3.2All patients with metastatic c...


...on 3.3Patients with favorable risk...


...tion 3.4Select patients with metastatic cl...


...dation 3.5The use of high dose interleu...


...endation from 2023 Rapid Recommendati...

...dation 3.6Treatment with IpiNivoCabo is not rec...


...ndation 4.1Nivolumab or cabozantinib...


...mmendation 4.2Patients progressing on combinati...


....3Patients who progress after initial therapy c...


...tion 4.4For patients on immunotherapy who experie...


...ecommendation 5.1For patients with low volum...


...tion 5.2For patients undergoing complete me...


...endation 6.1.1Patients with symptomatic...


...ndation 6.1.2Patients with bone metastases from...


...2. Second-Line or Greater Treatment...


...astases-Directed Treatment...


...ion 6.1.3No recommendation regarding opt...


...on 6.2.1Patients with brain metastases fro...


...mendation 6.2.2No recommendation regarding optimal...


...tion 6.3Patients with metastatic clear cell renal...


...re 4. Special Patient Subtypes


...ASCO believes that cancer clinical trials are vi...